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A 
ABBOTT LABS V. GARDNER, 387 
u.s. 136 (1967) 
Abbott Labs v. Gardner, 387 U.S. 136 (1967) is a leading 
Supreme Court case dealing with the " ripeness doctrine," 
which prevents courts from ruling on marrers that have 
no t yet developed into a form that is appropriate fo r 
judicial resolu tion. In the federal courts, the ripeness 
doctrine deri ves in pan from Article Ill of the Constitu-
tion , which gives the federal courts jurisdiction over "cases 
and controversies" bur not over abstract questions or 
hypothetica l disputes. Although ripeness concerns can 
arise in many contex ts, one recurrin g issue- and the one 
at rh e hea rt of the Abbott Labs litigation- is whether a 
person can seek a revi ew of an administrative regulation 
before the administrative agency attempts to enforce it. 
The Abbott Labs case concerned a new Food and 
Drug Administration (FDA) regulation implementing a 
federal stature that required drug labels and adve rtise-
ments to prominently display the drug's generic name. 
The main purpose of the stature was to in form doctors 
and patients that many expensive drugs were identical ro 
cheaper ge neric products. As the FDA interpreted the 
stature through this new regulation, the generic name had 
to appear every rime the brand name appeared. Several 
dozen drug companies and their trade association fil ed a 
lawsuit aga inst the FDA, contending that the regulation 
requ ired more extensive use of the generic name than the 
au thorizing stature contemplated . The government 
argued thar rhe regulation 's validity could nor be 
chall enged umil the agency enforced it against a violator. 
That is, the government contended rhar rhe suit was nor 
" ripe." 
The Supreme Court, in an op11110n by Justice John 
Marshall Harlan II , allowed the drug companies' 
challenge ro proceed. T he Court first considered whether 
rhe specific statures governing rhe FDA barred pre-
enforcement review. Statutory provisions express ly al-
lowed pre-enforcement judicial review in certain types of 
situations, bur rhis did nor persuade rhe Court rhar 
Congress meanr to preclude pre-enforcement review in 
cases in which the FDA statures did nor menrion such 
review. Having determ ined rhar rh ere was no implicit 
srarurory bar to review, rh e Court turn ed to more general 
principles of rhe ripeness doctrin e. The Court stared rhar 
rhe ripeness inquiry has " a twofo ld aspect, requiring us to 
evaluate both rh e flrn ess of rhe issues for judicial decision 
and the hardship to rh e parries of wirhholding court 
consideration ." 
By applying these standards, the Court determined 
rhar rhe companies' chall enge to the regulation cou ld be 
decided without waiting for any furth er factual develop-
mem, because it presented a purely legal question rega rding 
the agency's statutory authoriry ro issue rh e regulatio n. 
Further, turn ing to rhe consideration of hardship, rhe 
Court stared rhar rhe regulation was harming rhe 
companies even before enforcemem , because in order to 
comply they wou ld have ro spend a great deal of money to 
prepare new labels. Yer if rh ey did nor comply and waited 
ro be cited fo r a violarion , they f.1ced serious penalti es . 
G iven rhe dilemma hieing rh e companies, rhe Court 
decided it would be inappropriate ro delay a ruling. 
T hree justices, led by Justi ce Abe Forras, sharply 
dissented. T hey argued that the statutory scherne did nor 
al low for pre-enforcement revi ew, and rhar these FDA 
regulations had ro be challenged in rhe contex t of an 
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enfo rcement action. T hey also con tended th at even if 
review were otherwise ava il ab le un de r th e govern ing 
statu tes, this parti cular case d id no t p resent a co ncrete 
d ispute ri pe fo r review. T he d issenters warned that the 
decision would endanger the public by allowi ng regul ated. 
en tities to delay fo r years the implemen tatio n of 
regu lat ions meant to protect public heath and safe ty, a 
harm that far ou tweighed the hardship on the drug 
com panies . 
Abbott Labs v. Gardner was decided at the same time 
as two o ther related cases in volving FDA regul ations. O ne 
of those cases, Toilet Goods Assn. v. Gardner, 387 U.S. 158 
( 1967), provides a use ful contras t. H ere, the C ourt 
d ism issed the su it on ri peness grou nds. T he lawsuit 
in volved a chall enge to the va lid ity of an FDA regul ation 
that required manufactu rers of co lo r add itives to provide 
FDA inspectors with access to their faciliti es and fo rmul as. 
T he C oun dete rmin ed th at a p roper reso lu t ion of the case 
required further f<1ctual development rega rd ing how and 
why the FDA would carry out the inspect io ns, which the 
agency had not yet cond ucted . T urning to the issue of 
hardships, the C oun stated th at the regulati on did not 
require the manu facturers to change any of their present 
processes in o rder to comply, and th at the risk of hardship 
was roo specul ati ve. 
T he Abbott Labs li tigati on marked an impo rtant 
turnin g point. Befo re the case, pre-enforcement review of 
agency action was rare. AfteJwards, it became a fami li ar 
feature of the admi nistrat ive state. In addi tio n, whil e 
Abbott Labs arose in the particular co n tex t of administ ra-
tive law, its two-part ri peness inqu iry is co mmo nl y cited 
in other com exrs as well. 
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